Bourke J, Bourke M, Boutcher S, Bowden J, Bowen J, Bowring B, Boyce C, ..... Majeed J, Makar A, Makohon R, Malcher P, Malcolm HE, Malcolm M, Mallett S,.
Oct 8, 2018 - to improve health-care provider practices in low-income and middle-income ...... HCPPR staff will also provide technical assistance (to the extent that .... Grimshaw JM, Thomas RE, MacLennan G, Fraser C, Ramsay C, Vale L et al. ..... (s
D, Holland M, Hollins B, Homewood M, Hong Zhou A, Honig J, Honigman S, Hookham .... McAllan A, McCallum H, McCann N, McCarthy A, McCleary A, McClelland R, McConville DS, McCorkell J, ...... Arch Clin Neuropsychol 2003;18:153-164.
Jul 6, 2018 - Acceptable devices for tying cord in the home must be boiled and be ... In the home, antibiotic or antiseptic should be applied to the stump.
CTSK chr1:150774000. Not Applicable chr1:157074000. Inversion. 6,300,000 chr1:150774000/-/chr1:157074000/+ and chr1:157074000/-/chr1:150774000/+.
scalp. Cutis 2013;92:291-6. 50. Garza I. The trigeminal trophic syndrome: an unusual cause of face .... Neurocutaneous disease: Neurocutaneous dysesthesias.
The model had a time cycle of one-month, believed sufficiently short that half cycle correction was not performed and both costs and health were discounted at a.
May 16, 2018 - ... using Gelcompar II (Applied Maths, SintMartens Latem, Belgium). .... 104. 16/04/2015. H.influenzaeS.aureus. H.influenzae, S.aureus, B.
Jan 17, 2018 - Table S 6: Dictionary for coding signs and symptoms of ... Adverse events reported as resulting in Death (MedDRA coding) ...... (https://www.astmh.org/ASTMH/media/Documents/ASTMH2014AbstractBookFINAL.pdf) Abstract.
Mar 19, 2018 - mortality at ages 35-74 years from a vascular, renal or infectious cause, by A) ... with no diagnosed or undiagnosed diabetes at recruitment. 10.
Mar 15, 2018 - Supplement to: Hawcutt D B, Francis B, Carr D F, et al. Susceptibility to .... Nick Wild), Preston Hospital (Dr Mahmood), Barrow in Furness Hospital (Dr Olabi), Bradford Hospital. (Dr Moya) ..... Blair J, Lancaster G, Titman A, et al.
Supplementary Appendix Should Diabetes Mellitus be a Compelling Indication for Renin Angiotensin System Blockers? Insights from a Systematic Review and Meta-Analysis of Randomized Trials
Sripal Bangalore, MD, MHA, Robert Fakheri, MD, Bora Toklu, MD, Franz H. Messerli, MD
This appendix has been provided by the authors to give readers additional information about their work.
1
Contents Figure S1. Study selection ............................................................................................................... 3 Figure S2. Funnel Plot: RAS blockers versus other antihypertensive agents for the outcome of death ............................................................................................................................................... 4 Figure S3. Funnel Plot: RAS blockers versus other antihypertensive agents for the outcome of cardiovascular death ....................................................................................................................... 5 Figure S4. Funnel Plot: RAS blockers versus other antihypertensive agents for the outcome of myocardial infarction ...................................................................................................................... 6 Figure S5. Funnel Plot: RAS blockers versus other antihypertensive agents for the outcome of angina pectoris ................................................................................................................................ 7 Figure S6. Funnel Plot: RAS blockers versus other antihypertensive agents for the outcome of stroke .............................................................................................................................................. 8 Figure S7. Funnel Plot: RAS blockers versus other antihypertensive agents for the outcome of heart failure .................................................................................................................................... 9 Figure S8. Funnel Plot: RAS blockers versus other antihypertensive agents for the outcome of death ............................................................................................................................................. 10 Figure S9. Funnel Plot: RAS blockers versus other antihypertensive agents for the outcome of end stage renal disease................................................................................................................. 11 Figure S10. Funnel Plot: RAS blockers versus other antihypertensive agents for the outcome of drug withdrawal due to adverse effects ....................................................................................... 12 Table S1. Details of Search Terms ................................................................................................ 13 Table S2. Baseline Characteristics of the Clinical Trials included in the Meta-analysis ............... 14 Table S3. RAS blockers vs. other antihypertensive agents: Sensitivity analysis excluding impaired fasting glucose cohorts ................................................................................................................. 16 References .................................................................................................................................... 17
2
Figure S1. Study selection
Records identified through database search using terms “AngiotensinConverting enzyme inhibitor”, “angiotensin receptor antagonist”, and limited to RCT, Humans (n=11120) Duplicate studies (n=2010) Records excluded on the basis of title and/or abstract (n=8545)
Full-text articles assessed for eligibility (n=565) Sample size
